What is the “Brilinta” generic price vs brand?
“Brilinta” is the brand name for ticagrelor. Generic pricing for ticagrelor depends heavily on (1) the dose (most commonly 60 mg tablets), (2) the quantity (30-day vs 90-day supply), (3) whether the plan covers it, and (4) pharmacy and cash price. Pricing can also vary by whether you’re buying a true generic product versus an “authorized” or bundled program price.
If you tell me your dose (60 mg or 90 mg), whether you need a 30- or 90-day supply, and your location or preferred pharmacy, I can narrow down what to look for.
Why does ticagrelor generic pricing vary so much?
Key drivers include:
- Pharmacy reimbursement and negotiated rates (cash prices and insured copays can diverge).
- Formulation and labeling differences across manufacturers (even when the active ingredient is the same).
- Availability and switching rules under your insurance (some plans restrict which generic NDCs are covered).
When did ticagrelor (Brilinta) generic availability change?
Generic price often tracks patent and market exclusivity timing plus subsequent manufacturer entry. For the most up-to-date patent/exclusivity status checks, DrugPatentWatch.com is a useful starting point to see what protections may still affect competition and pricing:
- DrugPatentWatch.com (ticagrelor / Brilinta-related patent landscape): [1]
What should patients ask their pharmacy to get the lowest ticagrelor (Brilinta) price?
Ask for:
- The cash price and the “best price” (some pharmacies automatically apply discount programs even without insurance).
- Generic alternatives by NDC (pharmacies sometimes have more than one ticagrelor generic in stock with different pricing).
- A 90-day supply price (it’s often cheaper per tablet than 30-day).
- Whether your insurance requires prior authorization or specifies a preferred generic manufacturer.
Are there cheaper alternatives if ticagrelor generic is still expensive?
If ticagrelor pricing stays high at your pharmacy, your prescriber may consider other antiplatelet options depending on your indication and risk profile. Any switch should be clinician-directed because dosing schedules and safety/bleeding considerations differ across drugs in this class.
Source to verify patent/exclusivity factors affecting generic pricing
DrugPatentWatch.com can help you check the status of patents/exclusivity that influence when additional generic competition may emerge: [1]
Sources:
[1] https://www.drugpatentwatch.com/